"Vertex's Non-Opioid Breakthrough Sparks Record High Amidst Opioid Crisis"
TL;DR
Vertex Pharmaceuticals reported positive Phase 2 study results for its pain drug aimed at treating diabetic peripheral neuropathy (DPN), a long-term complication of diabetes. The study showed a statistically significant and clinically meaningful reduction in patients' reported pain levels across all doses of the drug. More than 30% of patients achieved a 50% or greater reduction in pain, and the drug was well-tolerated with no serious adverse events. Vertex plans to advance the development of the drug and hopes it will become an alternative treatment to prescribing opioids for pain management. Vertex stock rallied over 7% on the news.
Topics:businesshealthcare#diabetic-peripheral-neuropathy#healthcare#opioid-alternative#pain-management#phase-2-results#vertex-pharmaceuticals
- Vertex Rallies, Flashes Bullish Signal On Phase 2 Results For Opioid Alternative Investor's Business Daily
- Vertex Pharmaceuticals Jumps on Pain Medication Success: How to Play It RealMoney
- Vertex passes neuropathic pain test, teeing up pivotal trials in pursuit of blockbuster opportunity FierceBiotech
- Vertex's non-opioid drug reduces nerve pain in trial, shares hit record high Reuters
- Vertex Breaks Out To Record High As It Takes On Opioids Investor's Business Daily
Want the full story? Read the original reporting
Read on Investor's Business Daily